ARNI Pharmacology — Sacubitril/Valsartan

• Neprilysin Inhibition (Sacubitril Component): Neprilysin is a neutral endopeptidase that degrades natriuretic peptides (ANP and BNP), endothelin, and bradykinin. Inhibition of neprilysin prevents breakdown of these cardioprotective peptides, leading to: (1) increased ANP/BNP signaling via natriuretic peptide receptors, promoting vasodilation, natriuresis, and reduced aldosterone secretion; (2) enhanced bradykinin activity with additional vasodilation and anti-inflammatory effects; (3) reduced endothelin-mediated vasoconstriction and fibrosis. The net result is improved renal sodium excretion, reduced preload and afterload, and decreased myocardial fibrosis.

• Angiotensin II Receptor Blockade (Valsartan Component): The ARB portion blocks AT1 receptors on vascular smooth muscle, cardiac myocytes, and fibroblasts, preventing angiotensin II-mediated vasoconstriction, hypertrophy, inflammation, and fibrosis. This component maintains RAAS suppression while the neprilysin inhibitor paradoxically increases angiotensin II levels—a phenomenon that prevents compensatory RAAS activation and maintains the cardioprotective balance.

• Synergistic Cardioprotective Effects: The combination produces greater hemodynamic improvement than either agent alone. Reduced afterload and preload decrease myocardial oxygen demand, while anti-fibrotic effects reverse adverse left ventricular remodeling. Enhanced natriuretic peptide signaling activates guanylate cyclase, increasing cGMP and promoting cardiomyocyte relaxation and improved diastolic function.

• Heart Failure with Reduced Ejection Fraction (HFrEF): Primary indication, particularly NYHA Class II-III symptoms with EF ≤40%; shown to reduce mortality and hospitalizations in landmark PARADIGM-HF trial compared to enalapril

• Acute Decompensated Heart Failure: Evidence supports initiation or up-titration in hospitalized patients; reduces rehospitalization risk post-discharge

• High-Risk Patients for HF Development: Emerging data in post-MI patients with reduced EF and asymptomatic LV dysfunction suggests early initiation may prevent progression

• Chronic Kidney Disease with Proteinuria: Reduces proteinuria and slows GFR decline, though requires careful monitoring of potassium and creatinine

• Hypertension with LV Hypertrophy: Limited but growing evidence for regression of LV mass

Clinical Context for Initiation

• Symptomatic Dyspnea: Exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea indicating fluid overload; sacubitril/valsartan improves natriuresis and symptom burden

• Reduced Exercise Tolerance: NYHA Class II-III limitations; improves functional capacity through afterload reduction and improved cardiac output

• Prior ACE-I/ARB Intolerance: Persistent dry cough from ACE inhibitor use—neprilysin inhibition still provides protection while avoiding cough-inducing bradykinin accumulation; angioedema history requires caution but pure ARB component may be better tolerated than ACE-I

• Physical Exam Findings in HFrEF Patients:
• Elevated JVP, peripheral edema, hepatomegaly (which improve with therapy)
• S3 gallop, laterally displaced apical impulse (signs of systolic dysfunction)
• Cool extremities and reduced pulse pressure indicating low cardiac output

• Hypotension and Symptomatic Bradycardia: May occur during titration, requiring dose adjustment rather than discontinuation

Diagnostic Approach in HFrEF Candidates for ARNI Therapy

• Ejection Fraction Assessment: Transthoracic echocardiography demonstrating EF ≤40% is prerequisite; must document systolic dysfunction to justify ARNI initiation over other agents

• Biomarkers: Elevated BNP (>100 pg/mL) or NT-proBNP (>125 pg/mL at rest) support HF diagnosis; these markers may further rise initially after ARNI initiation (due to neprilysin inhibition) but should trend downward with continued therapy—this rise does NOT indicate worsening and should not prompt drug discontinuation

• Baseline Laboratory Parameters (mandatory before initiation):
• Serum creatinine and eGFR: Establish baseline renal function; ARNI can cause acute kidney injury (AKI) in specific settings (see complications); generally safe if eGFR >15 mL/min/1.73m²
• Potassium level: Must be <5.5 mEq/L; ARNI increases potassium retention; hyperkalemia is major dose-limiting toxicity
• Sodium level: Hyponatremia (<130 mEq/L) is relative contraindication; ARNI promotes sodium excretion and worsens hyponatremia
• Blood pressure: SBP should ideally be ≥100 mmHg; patients with SBP <90 mmHg often cannot tolerate target ARNI doses

• 12-Lead ECG: Assess for atrial fibrillation (requires rate control optimization before ARNI), QRS duration (wide QRS may warrant CRT evaluation), and baseline rhythm

• Cardiac MRI: May be indicated to exclude specific etiologies (infiltrative disease, myocarditis) when echocardiographic diagnosis uncertain

• Diagnostic Criteria for HFrEF:
• EF ≤40%
• Symptoms of HF (or history thereof)
• Elevated natriuretic peptides OR objective evidence of structural abnormality

Pharmacological Management with Sacubitril/Valsartan

• First-Line Therapy in HFrEF: Sacubitril/valsartan is now preferred over ACE-I/ARB monotherapy based on PARADIGM-HF superiority data; superior to lisinopril in reducing cardiovascular mortality and HF hospitalizations. Available formulations: 24/26 mg, 49/51 mg, 97/103 mg (sacubitril/valsartan respectively) twice daily.

• Initiation and Titration Protocol:
• Start at 24/26 mg twice daily in patients with SBP 100-120 mmHg or eGFR 30-60 mL/min/1.73m²
• Target dose: 97/103 mg twice daily (maximum therapeutic benefit)
• Titration interval: Increase every 2-4 weeks if SBP >100 mmHg and potassium <5.5 mEq/L
• May require slower titration in elderly (>75 years), hypotensive (SBP 90-100), or renal impairment patients
• Hold or reduce dose if SBP <90 mmHg persistently, K+ >6.0 mEq/L, or serum creatinine doubles from baseline

• Mechanism-Based Efficacy:
• Reduces HF hospitalizations by ~21% vs. ACE-I monotherapy (PARADIGM-HF)
• Reduces cardiovascular mortality by ~20%
• Improves symptoms and exercise tolerance through hemodynamic optimization
• Slows LV remodeling and improves EF trajectory over 12-24 months

• Transition from ACE-I/ARB:
• Washout Period: Discontinue current ACE-I or ARB for 24-48 hours before starting ARNI (reduces first-dose hypotension risk)
• Do NOT combine with ACE-I, ARB, or other ARNI (risk of severe hypotension, hyperkalemia, renal deterioration)
• Exception: ARB/ACE-I monotherapy may be continued temporarily in acute decompensated HF if ARNI unavailable

• Combination with Other HF Therapies:
• Beta-blockers: Continue or initiate; synergistic neurohormonal suppression; no dose adjustment needed
• Aldosterone Antagonists: Spironolactone/eplerenone continue at baseline doses; hyperkalemia risk increases with combination—monitor K+ closely
• SGLT2 Inhibitors: Emerging evidence supports addition (dapagliflozin, empagliflozin); additive mortality benefit and independent renal protection
• Ivabradine: May be added if heart rate remains elevated despite beta-blockers
• Diuretics: Continue or adjust based on volume status; ARNI enhances diuretic efficacy
• Hydralazine/Nitrate: May reduce ARNI dose if combined due to additive blood pressure reduction

• Non-Pharmacological Measures:
• Sodium restriction: <3 g/day reduces volume overload; patient education critical
• Fluid management: 1.5-2 L daily restriction in advanced HF with congestion
• Exercise training: Cardiac rehab improves functional capacity and outcomes; ARNI optimizes hemodynamics during exercise
• Implantable devices: CRT-D evaluation for EF ≤35% and QRS ≥120 ms; ARNI optimizes candidacy
• ICD therapy: Per current guidelines (EF ≤35%, NYHA II-III or primary prevention); ARNI complements device therapy

• Monitoring Protocol:
• Baseline: Renal function, potassium, sodium, blood pressure, symptom assessment
• Week 2: Blood pressure and symptoms check; earlier if dose escalation
• Week 4-6: Serum creatinine, potassium, sodium (critical for safety)
• Every 3 months: Routine labs once stable on maintenance dose
• Every 6-12 months: Echocardiography to assess EF trajectory and guide device therapy decisions
• Symptom-Directed: Reassess if dyspnea worsens, syncope, orthostatic symptoms develop

Adverse Effects and Management

• Hypotension: Most common dose-limiting adverse effect; occurs in ~10-15% of HFrEF patients. Symptomatic hypotension (dizziness, syncope, presyncope) requires dose reduction or holding dose. Asymptomatic SBP 90-95 mmHg often tolerable. Management: reduce diuretic dose if volume replete, space dosing intervals, reduce ARNI dose, or temporarily discontinue other vasodilators. True refractory hypotension may necessitate discontinuation, though often temporary during up-titration.

• Hyperkalemia: Second most common serious adverse effect; incidence ~4% at target dose, higher with concurrent ACE-I/ARB, spironolactone, NSAIDs, or renal impairment. Risk increases with baseline eGFR <30 mL/min/1.73m². Serum K+ >6.0 mEq/L requires dose reduction or holding. Management: restrict dietary potassium, discontinue aldosterone antagonist if K+ >6.5 mEq/L, consider patiromer/sodium zirconium cyclosilicate for recurrent hyperkalemia. Check K+ 1-2 weeks after initiation and dose increases.

• Acute Kidney Injury (AKI) and Creatinine Elevation: Expected initial increase in serum creatinine (up to 30%) and decrease in eGFR within first 2-4 weeks due to hemodynamic changes (reduced glomerular pressure from afterload reduction). This adaptive response is NOT worsening renal disease and should not prompt discontinuation if increase <30%. Monitor trajectory: if creatinine stabilizes or improves by 8-12 weeks, continue therapy. True deterioration (>30% increase persisting beyond 4 weeks, symptomatic oliguria) warrants investigation for drug-induced injury vs. volume depletion. Contraindication: baseline eGFR <15 mL/min/1.73m² or dialysis-dependent.

• Hyponatremia: Rare but serious; ARNI promotes sodium excretion through enhanced natriuresis. More common in advanced HF, concurrent diuretic overuse, or SIADH. Serum sodium <130 mEq/L is relative contraindication. Management: fluid restriction, loop diuretic optimization, consider vaptans in symptomatic hyponatremia. Check sodium at baseline and if symptoms (confusion, seizures, altered mental status) develop.

• Persistent Dry Cough: Notably ABSENT with ARNI compared to ACE-I (occurs in <5-10% vs. 15-20% with ACE-I) because neprilysin inhibition avoids excessive bradykinin accumulation. This is major advantage in ACE-I-intolerant patients.

• Angioedema: Rare but serious; can occur even with ARB component alone, though much less frequent than with ACE-I. History of angioedema with ACE-I is relative contraindication—ARB monotherapy may be safer. If angioedema develops, discontinue immediately and avoid all ACE-I/ARB/ARNI in future (cross-reactivity risk).

• Syncope and Presyncope: Occurs with rapid up-titration or in patients with autonomic dysfunction, advanced age, or concurrent vasodilators. Assess for orthostatic vital signs; slow titration and reduce diuretic burden.

• Fetal Toxicity: Contraindicated in pregnancy; RAAS inhibition teratogenic in second/third trimester (renal dysgenesis, oligohydramnios, IUGR). Women of childbearing age require effective contraception and counseling.

• Cough-Variant: If cough develops despite ARNI use, investigate alternative etiologies (ACE-I use in past, pulmonary edema, infection) before attributing to ARNI.

• Life-Threatening Complication—Severe Hyperkalemia (K+ >7.0 mEq/L): May cause life-threatening cardiac arrhythmias (peaked T waves, widened QRS, bradycardia, cardiac arrest). Requires emergent management: calcium gluconate IV for cardiac membrane stabilization, insulin + glucose, beta-agonists, sodium polystyrene sulfonate or patiromer, emergent dialysis if refractory. Discontinue ARNI, hold all RAAS inhibitors and NSAIDs. Resume ARNI cautiously at lower dose if hyperkalemia resolves.

Outcomes and Natural History in ARNI-Treated HFrEF

Prognostic factors modifying ARNI benefit

• EF trajectory: Patients achieving EF improvement to >40% have improved long-term survival; ARNI optimizes remodeling potential
• Age: Benefit consistent across age groups; elderly patients tolerate ARNI well with careful titration
• Etiology: Ischemic HF shows similar ARNI

Mechanism buzzwords

• Sacubitril is a prodrug: hydrolyzed to the active metabolite LBQ657, which inhibits neprilysin (neutral endopeptidase). Valsartan blocks AT1 receptors — the ARB is required because neprilysin inhibition alone raises angiotensin II.
• Never give with an ACE inhibitor: simultaneous blockade of both bradykinin-degrading pathways causes angioedema (the lesson of the abandoned vasopeptidase inhibitor era). The classic stem tests the washout: stop the ACE inhibitor and wait 36 hours before the first ARNI dose (no washout needed when switching from an ARB).

The biomarker trick examiners love

• BNP is a neprilysin substrate; NT-proBNP is not. Expect BNP to rise on ARNI while NT-proBNP falls — a rising BNP is not decompensation and is not a reason to stop the drug. Use NT-proBNP for monitoring.

Single best next step patterns

• Creatinine rises <30% with stable volume status: continue therapy and recheck — hemodynamic, not tubular injury.
• Hyperkalemia (K⁺ near or above 5.5): address diet, NSAIDs, and the MRA dose before abandoning the ARNI; a potassium binder is preferable to losing guideline-directed therapy.
• Prior ACE-inhibitor angioedema: ARNI is contraindicated. Choose a different class.

Guideline framing

• Per the 2022 AHA/ACC/HFSA Heart Failure Guideline, ARNI is preferred over ACE inhibitor or ARB in chronic symptomatic HFrEF, and the four pillars are ARNI (or ACEI/ARB), evidence-based beta blocker, MRA, and SGLT2 inhibitor — all four, initiated and titrated in parallel rather than sequentially.
• PARADIGM-HF compared sacubitril/valsartan with enalapril (not with placebo) — the distractor answer is "no proven benefit over ACE inhibitor." PIONEER-HF supports in-hospital initiation once hemodynamically stable.
• HFpEF: PARAGON-HF did not meet its primary endpoint; the guideline offers only a weak (may-be-considered) role, favoring patients at the lower end of the EF spectrum. Do not call ARNI first-line for HFpEF.

Absolute don'ts

• Pregnancy — fetal renal toxicity, as with any RAAS blocker; and avoid aliskiren combination, especially in diabetes.